Navigation Links
Study Supports Cost-Effectiveness of Medtronic's Spasticity,Treatment for Children with Cerebral Palsy

MINNEAPOLIS--(BUSINESS WIRE)--Apr 26, 2007 - A new study published in the current issue of the Journal of Child Neurology indicates that a treatment from Medtronic, Inc. (NYSE:MDT), for spasticity in children with cerebral palsy improves their quality of life and is cost-effective compared to other established cost-effective treatments. The findings of this Medtronic-sponsored study should expand access to the treatment, known as Medtronic ITB Therapy(SM) (Intrathecal Baclofen Therapy).

Cerebral palsy affects an estimated 764,000 people in the United States, according to United Cerebral Palsy, with approximately 8,000 babies and 1,200 to 1,500 preschool-age children diagnosed with the condition each year. Caused by damage to one or more areas of the developing brain, cerebral palsy is characterized by an inability to control motor function fully, particularly muscle control and coordination.

The most common form of cerebral palsy involves spasticity - tight, stiff muscles that make coordinated movement (especially of the arms and legs) difficult or uncontrollable. Up to 80 percent of children with cerebral palsy develop spasticity, which can be painful and limit functional ability for the patient, and tax the patient's family physically, emotionally, and financially.

Medtronic ITB Therapy, which uses the company's SynchroMed(R) implantable infusion system to deliver a muscle relaxant directly to the fluid-filled area surrounding the spinal cord, can effectively reduce severe spasticity with fewer side-effects than oral medication. By reducing spasticity, ITB Therapy may also improve function, quality of life, and ease of care.

Despite the treatment's well-demonstrated clinical efficacy, ITB Therapy remains underused - in large part because of concerns about the cost of the pump and the surgery to implant it.

"The cost of ITB Therapy should not prevent pediatric patients with spastici
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:12/22/2014)... NxStage Medical, Inc. (NASDAQ: NXTM ... announced today that the U.S. Food and Drug ... perform hemodialysis overnight while the patient is at ... System One is the first and only hemodialysis ... Home nocturnal hemodialysis is an ...
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... issued the following open letter to shareholders from ... Med. Sc. Dear RXi Shareholders, ... of inaccurate statements posted on certain social media ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... Raylene Riha and her husband, Michael, filed suit today ... seeking compensation for injuries caused by failures of Raylene,s ... been recalled.  John David Hart of the Law Offices ... the attorney representing Raylene and Michael Riha in the ...
... Watson Pharmaceuticals, Inc. (NYSE: WPI ) ...  and Watson Laboratories, Inc. -- Florida, (collectively "Watson") ... U.S. Food and Drug Administration (FDA) seeking approval ... 10,15, 20, 30, 40, 60 and 80 mg ...
Cached Medicine Technology:Law Offices of John David Hart: DePuy Recalled Hip Device Lawsuit Filed by Houston Woman 2Watson Confirms OxyContin® Patent Challenge 2Watson Confirms OxyContin® Patent Challenge 3
(Date:12/26/2014)... Orlando, FL (PRWEB) December 26, 2014 ... visitor health insurance in the USA, announced today a ... to assist members in choosing the right plan for ... take the complexity out of the selection process when ... premiums by age group with only a few clicks. ...
(Date:12/25/2014)... The microscopy market is estimated to ... $5,756.0 million by 2019. Optical microscopy is the ... microscopes product segment is expected to show the ... focus on nanotechnology, technological advancements, and increasing federal ... , Get Full Copy of Report @ ...
(Date:12/25/2014)... 26, 2014 The report “TS-1 (Colorectal ... on the current treatment landscape, unmet needs, current pipeline ... is an anti-cancer drug which is typically used for ... also used for treating gastric cancer and pancreatic cancer. ... The drug was first approved in 1999 in Japan ...
(Date:12/25/2014)... Dylan Queen, a famous online company supplying women’s special ... prom dresses, most of which are priced under $200. ... the promotion is valid until Jan. 22, 2015; the ... market. , The prom dresses in this new collection ... strapless, empire strapless chiffon, one shoulder, floor-length, V-neck beading, ...
(Date:12/25/2014)... December 25, 2014 Helen Harris’ RP ... Woodland Hills, California after an 8 year battle with ... Christmas Eve evening in her home in Woodland Hills ... breast cancer. , As the founder ... years, she pioneered and championed many of today's greatest ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... technique could speed the diagnosis, French researchers say ... radiologists report they,ve simplified a method of scanning ... making it easier to diagnose the mind-robbing condition. ... routinely using the approach, but early tests are ...
... DIEGO, June 24 Behavioral Risk Management is ... the strong message from,a survey conducted by the ... and effectiveness in Behavioral Risk,Management., Additionally, survey ... beyond an emerging focus area to one that ...
... Abusing Prescription Medications Get ... or Friend, NEW YORK, June 24 A house ... secure, yet it is here that teens are,prone to get ... drug misuse and abuse, the Partnership for a Drug-Free,America(R) and ...
... announced the launch of the 3M™ Filtron™ 1900 tie-on ... seeking a premium surgical mask. The new 3M ... a rayon outerlayer to deliver increased breathability and comfort, ... a popular "duckbill" design, the 3M Filtron 1900 surgical ...
... Year Revenue Guidance to a range of $395 Million to $405 ... ... Revenue of $101.9 million, up 57.4% over first quarter 2007 - Gross ... income of $9.6 million, up 135.4% over first quarter 2007, WARSAW, Ind., June ...
... Way to Fight Common Illnesses, HOLLYWOOD, Calif., June ... site, http://www.help2getbetter.com, and the sale,of online sick ... fight common illnesses. What makes these sick packs unique ... but come packaged,together conveniently in one- or two-dose portion ...
Cached Medicine News:Health News:Brain Scans Detect Alzheimer's Disease Quickly 2Health News:Brain Scans Detect Alzheimer's Disease Quickly 3Health News:Behavioral Risk in the Workplace: Behavioral Risk Management Continues to be an Important Best Practice Area for Employers 2Health News:Abbott and Partnership for a Drug-Free America Launch 'Not In My House' to Help Parents Secure Their Homes from Teen Prescription Drug Misuse and Abuse 2Health News:Abbott and Partnership for a Drug-Free America Launch 'Not In My House' to Help Parents Secure Their Homes from Teen Prescription Drug Misuse and Abuse 3Health News:3M Health Care launches new high-performance surgical mask 2Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 2Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 3Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 4Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 5Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 6Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 7Health News:Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million 8Health News:Launch of help2getbetter.com Provides Convenience and Portability to Household Medicines 2
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
For the quantitative in vitro determination of Digitoxin in human serum....
For the quantitative in vitro determination of Phenytoin in human serum....
For the quantitative in vitro determination of Phenobarbital in human serum....
Medicine Products: